Gain Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Gain Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2024.
  • Gain Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 59.3 %, a 22.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 59.3 +10.9 +22.6% Sep 30, 2024
Q2 2024 64.8 +29.1 +81.3% Jun 30, 2024
Q1 2024 65.3 +39.1 +149% Mar 31, 2024
Q4 2023 56.7 +35.2 +164% Dec 31, 2023
Q3 2023 48.3 +30.7 +175% Sep 30, 2023
Q2 2023 35.8 Jun 30, 2023
Q1 2023 26.2 Mar 31, 2023
Q4 2022 21.4 Dec 31, 2022
Q3 2022 17.6 Sep 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.